WO2003075846A3 - Uses of monoclonal antibody 8h9 - Google Patents

Uses of monoclonal antibody 8h9 Download PDF

Info

Publication number
WO2003075846A3
WO2003075846A3 PCT/US2003/007004 US0307004W WO03075846A3 WO 2003075846 A3 WO2003075846 A3 WO 2003075846A3 US 0307004 W US0307004 W US 0307004W WO 03075846 A3 WO03075846 A3 WO 03075846A3
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibody
provides
derivative
binding
effective amount
Prior art date
Application number
PCT/US2003/007004
Other languages
French (fr)
Other versions
WO2003075846A2 (en
Inventor
Nai-Kong V Cheung
Original Assignee
Sloan Kettering Inst Cancer
Nai-Kong V Cheung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/097,558 external-priority patent/US7737258B2/en
Priority claimed from US10/273,762 external-priority patent/US7666424B2/en
Priority to AT03716369T priority Critical patent/ATE490274T1/en
Priority to EP03716369A priority patent/EP1572077B1/en
Priority to US10/505,658 priority patent/US7740845B2/en
Priority to DE60335203T priority patent/DE60335203D1/en
Application filed by Sloan Kettering Inst Cancer, Nai-Kong V Cheung filed Critical Sloan Kettering Inst Cancer
Priority to AU2003220079A priority patent/AU2003220079A1/en
Priority to CA2478082A priority patent/CA2478082C/en
Publication of WO2003075846A2 publication Critical patent/WO2003075846A2/en
Publication of WO2003075846A3 publication Critical patent/WO2003075846A3/en
Priority to US12/721,798 priority patent/US8414892B2/en
Priority to US13/858,234 priority patent/US9062110B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Abstract

This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier.This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier.This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen. This invention also provides different uses of the monoclonal antibody 8H9 or its derivative.
PCT/US2003/007004 2000-10-18 2003-03-06 Uses of monoclonal antibody 8h9 WO2003075846A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA2478082A CA2478082C (en) 2002-03-08 2003-03-06 Uses of monoclonal antibody 8h9
AU2003220079A AU2003220079A1 (en) 2002-03-08 2003-03-06 Uses of monoclonal antibody 8h9
EP03716369A EP1572077B1 (en) 2002-03-08 2003-03-06 Uses of monoclonal antibody 8h9
US10/505,658 US7740845B2 (en) 2000-10-18 2003-03-06 Uses of monoclonal antibody 8H9
DE60335203T DE60335203D1 (en) 2002-03-08 2003-03-06 USES OF MONOCLONAL ANTIBODY 8H9
AT03716369T ATE490274T1 (en) 2002-03-08 2003-03-06 USES OF MONOCLONAL ANTIBODY 8H9
US12/721,798 US8414892B2 (en) 2000-10-18 2010-03-11 Uses of monoclonal antibody 8H9
US13/858,234 US9062110B2 (en) 2000-10-18 2013-04-08 Uses of monoclonial antibody 8H9

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10/097,558 2002-03-08
US10/097,558 US7737258B2 (en) 2000-10-18 2002-03-08 Uses of monoclonal antibody 8H9
PCT/US2002/033331 WO2003033670A2 (en) 2001-10-17 2002-10-17 Method for preparation of single chain antibodies
US10/273,762 2002-10-17
US10/273,762 US7666424B2 (en) 2001-10-17 2002-10-17 Methods of preparing and using single chain anti-tumor antibodies
USPCT/US02/33331 2002-10-17

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
US10/273,762 Continuation-In-Part US7666424B2 (en) 2000-10-18 2002-10-17 Methods of preparing and using single chain anti-tumor antibodies
US10/273,762 Continuation US7666424B2 (en) 2000-10-18 2002-10-17 Methods of preparing and using single chain anti-tumor antibodies
PCT/US2002/033331 Continuation-In-Part WO2003033670A2 (en) 2000-10-18 2002-10-17 Method for preparation of single chain antibodies

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10505658 A-371-Of-International 2003-03-06
US12/721,798 Division US8414892B2 (en) 2000-10-18 2010-03-11 Uses of monoclonal antibody 8H9

Publications (2)

Publication Number Publication Date
WO2003075846A2 WO2003075846A2 (en) 2003-09-18
WO2003075846A3 true WO2003075846A3 (en) 2005-08-11

Family

ID=27808456

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/007004 WO2003075846A2 (en) 2000-10-18 2003-03-06 Uses of monoclonal antibody 8h9

Country Status (3)

Country Link
AU (1) AU2003220079A1 (en)
CA (1) CA2478082C (en)
WO (1) WO2003075846A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7740845B2 (en) 2000-10-18 2010-06-22 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US7737258B2 (en) 2000-10-18 2010-06-15 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US8414892B2 (en) 2000-10-18 2013-04-09 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US8501471B2 (en) 2000-10-18 2013-08-06 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
AU2003298794A1 (en) * 2002-12-02 2004-06-23 Us Gov Health & Human Serv Recombinant immunotoxin and use in treating tumors
EP2937360A1 (en) 2005-06-17 2015-10-28 Merck Sharp & Dohme Corp. Ilt3 binding molecules and uses therefor
JP5597793B2 (en) * 2006-06-19 2014-10-01 メルク・シャープ・アンド・ドーム・コーポレーション ILT3-binding molecules and uses thereof
EP2121008A4 (en) * 2007-03-22 2010-03-31 Sloan Kettering Inst Cancer Uses of monoclonal antibody 8h9
CA2826942C (en) 2011-02-11 2021-08-03 Memorial Sloan-Kettering Cancer Center Hla-restricted, peptide-specific antigen binding proteins
PE20141271A1 (en) 2011-04-01 2014-10-08 Sloan Kettering Inst Cancer T-CELL RECEPTOR TYPE ANTIBODIES SPECIFIC TO A WT1 PEPTIDE PRESENTED BY HLA-A2
US10865245B2 (en) 2014-12-23 2020-12-15 Full Spectrum Genetics, Inc. Anti-B7H3 binding compounds and uses thereof
WO2016106004A1 (en) 2014-12-23 2016-06-30 Full Spectrum Genetics, Inc. Novel anti-b7h3 binding compounds and uses thereof
EP3806848A2 (en) 2018-06-15 2021-04-21 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
MA55805A (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc METHODS OF MODULATING IMMUNE ACTIVITY
EP4022313A1 (en) 2019-08-30 2022-07-06 Y-Mabs Therapeutics, Inc. Immunohistochemical assessment of b7-h3 expression
JP2023509359A (en) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド Combination anticancer therapy with inducers of iron-dependent cell degradation
JP2023532339A (en) 2020-06-29 2023-07-27 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド Viruses engineered to promote sanotransmission and their use in treating cancer
JP2024512669A (en) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド Tanotransmission polypeptides and their use in the treatment of cancer
WO2023278641A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MODAK ET AL: "Monoclonal Antibody 8H9 Targets a Novel Cell Surface Antigen Expressed by a Wide Spectrum of Human Solid Tumors.", CANCER RESEARCH, vol. 61, 15 May 2001 (2001-05-15), pages 4048 - 4054, XP002974623 *
See also references of EP1572077A4 *

Also Published As

Publication number Publication date
CA2478082C (en) 2016-02-02
AU2003220079A8 (en) 2003-09-22
CA2478082A1 (en) 2003-09-18
AU2003220079A1 (en) 2003-09-22
WO2003075846A2 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
WO2003075846A3 (en) Uses of monoclonal antibody 8h9
WO2002032375A3 (en) Uses of monoclonal antibody 8h9
WO2003078468A3 (en) Use of an active substance that binds to cd28 for producing a pharmaceutical composition
AU2003294290A1 (en) Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
EP1572077A3 (en) Uses of monoclonal antibody 8h9
AU2001268855A1 (en) Single-domain antigen-binding antibody fragments derived from llama antibodies
WO2002022851A3 (en) Novel tumor-associated marker
WO2008079995A3 (en) Conjugate of natriuretic peptide and antibody constant region
WO2004058821A3 (en) Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
WO2006026759A3 (en) Humanized anti-beta7 antagonists and uses therefor
WO2008116219A3 (en) Uses of monoclonal antibody 8h9
PL354112A1 (en) Application of anti-ctla-4 antibodies
WO2002030985A3 (en) Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
WO1998057994A3 (en) Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
WO2007033230A3 (en) Anti-cd3 antibody formulations
WO2002030460A3 (en) Therapeutic antibodies
WO2002030986A3 (en) HUMANIZED ANTI-LT-β-R ANTIBODIES
WO2002016401A3 (en) Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof
AU2001233027A1 (en) Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
WO2006033700A3 (en) Her2 antibody composition
IL158643A (en) Anti-hmg monoclonal antibodies and compositions containing the same
WO2002075274A3 (en) Method and kit for following neurodegenerative diseases
EP1572077A4 (en) Uses of monoclonal antibody 8h9
WO2005000194A3 (en) Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
WO2001087233A3 (en) Anti-idiotypic antibody against fimh adhesin of uropathogenic type i-fimbriated escherichia coli, compositions and method of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10505658

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2478082

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003716369

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003716369

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP